Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Zacks Equity Research

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Zacks Equity Research

AngioDynamics (ANGO) Shows Solid Results from RAPID Database

by Zacks Equity Research

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

Zacks Equity Research

HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.

Zacks Equity Research

AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat

by Zacks Equity Research

AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.

Zacks Equity Research

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Zacks Equity Research

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Zacks Equity Research

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.

Zacks Equity Research

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

by Zacks Equity Research

Inogen (INGN) saw revenue decline within its Sales segment in Q3

Zacks Equity Research

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

by Zacks Equity Research

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.

Zacks Equity Research

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

by Zacks Equity Research

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Zacks Equity Research

Fresenius Medical (FMS) Stock Gains 5.6% on Q3 Earnings Beat

by Zacks Equity Research

Fresenius Medical's (FMS) third-quarter earnings benefit from stable segmental performance.

Zacks Equity Research

Change Healthcare (CHNG) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal second-quarter results benefit from solid performance in the Network Solutions segment.

Zacks Equity Research

Cardinal Health (CAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results reflect strong segmental performance.

Zacks Equity Research

AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results benefit from segmental growth.

Zacks Equity Research

Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.

Zacks Equity Research

Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.

Zacks Equity Research

Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.

Zacks Equity Research

McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.

Zacks Equity Research

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

by Zacks Equity Research

Accuray (ARAY) registered growth in Service revenues in Q1.